141 related articles for article (PubMed ID: 18334712)
1. Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
Stewart DJ
J Natl Cancer Inst; 2008 Mar; 100(6):445-6; author reply 446. PubMed ID: 18334712
[No Abstract] [Full Text] [Related]
2. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
3. Selecting promising treatments in randomized Phase II cancer trials with an active control.
Cheung YK
J Biopharm Stat; 2009; 19(3):494-508. PubMed ID: 19384691
[TBL] [Abstract][Full Text] [Related]
4. NSCLC drug targets acquire new visibility.
Friedrich MJ
J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
[No Abstract] [Full Text] [Related]
5. [Lung cancer].
Fischer B; Buhl R
Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in the treatment of advanced/metastatic NSCLC.
Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
Smit EF; Dingemans AM; Thunnissen FB; Hochstenbach MM; van Suylen RJ; Postmus PE
J Thorac Oncol; 2010 May; 5(5):719-20. PubMed ID: 20421765
[No Abstract] [Full Text] [Related]
8. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
10. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.
Dy GK; Hillman SL; Rowland KM; Molina JR; Steen PD; Wender DB; Nair S; Mandrekar S; Schild SE; Adjei AA;
Cancer; 2010 Dec; 116(24):5686-93. PubMed ID: 21218460
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Lim SM; Cho BC; Kim SW; Kang SY; Heo DS; Kim HT; Lee DH; Kim DW; Jung M; Choi JH; Shim HS; Choi JR; Kim JH
Lung Cancer; 2016 Mar; 93():1-8. PubMed ID: 26898607
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in non-small cell lung cancer.
Zhang J; Gold KA; Kim E
Expert Opin Investig Drugs; 2012 Sep; 21(9):1417-26. PubMed ID: 22725255
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
[TBL] [Abstract][Full Text] [Related]
14. [TRUST study: general practice relevant data on erlotinib in NSCLC].
Knabl A
Wien Med Wochenschr; 2007; 157(21-22):579-80. PubMed ID: 18157598
[No Abstract] [Full Text] [Related]
15. Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
Pazo Cid RA; Lao J; Lanzuela M
JAMA; 2011 Feb; 305(8):781; author reply 781. PubMed ID: 21343576
[No Abstract] [Full Text] [Related]
16. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
DeGrendele H
Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
[No Abstract] [Full Text] [Related]
17. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Gridelli C; Rossi A; Mongillo F; Bareschino M; Maione P; Ciardiello F
Clin Lung Cancer; 2007 May; 8(6):396-8. PubMed ID: 17562243
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Adjei AA; Molina JR; Mandrekar SJ; Marks R; Reid JR; Croghan G; Hanson LJ; Jett JR; Xia C; Lathia C; Simantov R
Clin Cancer Res; 2007 May; 13(9):2684-91. PubMed ID: 17473200
[TBL] [Abstract][Full Text] [Related]
19. CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Vroling L; Lind JS; de Haas RR; Verheul HM; van Hinsbergh VW; Broxterman HJ; Smit EF
Br J Cancer; 2010 Jan; 102(2):268-75. PubMed ID: 20010948
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib hydrochloride.
Minna JD; Dowell J
Nat Rev Drug Discov; 2005 May; Suppl():S14-5. PubMed ID: 15962526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]